These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 26761771)
21. NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Hegele RA; Guy J; Ban MR; Wang J Lipids Health Dis; 2005 Aug; 4():16. PubMed ID: 16098225 [TBL] [Abstract][Full Text] [Related]
22. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
23. Membrane topology of human NPC1L1, a key protein in enterohepatic cholesterol absorption. Wang J; Chu BB; Ge L; Li BL; Yan Y; Song BL J Lipid Res; 2009 Aug; 50(8):1653-62. PubMed ID: 19325169 [TBL] [Abstract][Full Text] [Related]
24. Bean peptides have higher in silico binding affinities than ezetimibe for the N-terminal domain of cholesterol receptor Niemann-Pick C1 Like-1. Real Hernandez LM; Gonzalez de Mejia E Peptides; 2017 Apr; 90():83-89. PubMed ID: 28259659 [TBL] [Abstract][Full Text] [Related]
25. Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer. Kobberø Lauridsen B; Stender S; Frikke-Schmidt R; Nordestgaard BG; Tybjærg-Hansen A Int J Epidemiol; 2017 Dec; 46(6):1777-1785. PubMed ID: 29106532 [TBL] [Abstract][Full Text] [Related]
27. First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene. Al-Hinai AT; Al-Abri A; Al-Dhuhli H; Al-Waili K; Al-Sabti H; Al-Yaarubi S; Al-Hashmi K; Banerjee Y; Al-Zakwani I; Al-Rasadi K Angiology; 2013 May; 64(4):287-92. PubMed ID: 23162007 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia. Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733 [TBL] [Abstract][Full Text] [Related]
29. Cholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 Like 1 [NPC1L1). Davis HR; Basso F; Hoos LM; Tetzloff G; Lally SM; Altmann SW Atheroscler Suppl; 2008 Sep; 9(2):77-81. PubMed ID: 18585981 [TBL] [Abstract][Full Text] [Related]
30. Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption. Zhang R; Liu W; Zeng J; Meng J; Jiang H; Wang J; Xing D Eur J Med Chem; 2022 Feb; 230():114111. PubMed ID: 35063734 [TBL] [Abstract][Full Text] [Related]
31. Niemann-Pick C1 Like 1 (NPC1L1) an intestinal sterol transporter. Davis HR; Altmann SW Biochim Biophys Acta; 2009 Jul; 1791(7):679-83. PubMed ID: 19272334 [TBL] [Abstract][Full Text] [Related]
32. Structural insights into the mechanism of human NPC1L1-mediated cholesterol uptake. Hu M; Yang F; Huang Y; You X; Liu D; Sun S; Sui SF Sci Adv; 2021 Jul; 7(29):. PubMed ID: 34272236 [TBL] [Abstract][Full Text] [Related]
33. Ezetimibe: rescued by randomization (clinical and mendelian). McPherson R; Hegele RA Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):e13-5. PubMed ID: 25550209 [No Abstract] [Full Text] [Related]
34. Class B type I scavenger receptor is responsible for the high affinity cholesterol binding activity of intestinal brush border membrane vesicles. Labonté ED; Howles PN; Granholm NA; Rojas JC; Davies JP; Ioannou YA; Hui DY Biochim Biophys Acta; 2007 Sep; 1771(9):1132-9. PubMed ID: 17442616 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393 [TBL] [Abstract][Full Text] [Related]
36. Ezetimibe interferes with cholesterol trafficking from the plasma membrane to the endoplasmic reticulum in CaCo-2 cells. Field FJ; Watt K; Mathur SN J Lipid Res; 2007 Aug; 48(8):1735-45. PubMed ID: 17473178 [TBL] [Abstract][Full Text] [Related]
37. Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. Descamps O; Tomassini JE; Lin J; Polis AB; Shah A; Brudi P; Hanson ME; Tershakovec AM Atherosclerosis; 2015 Jun; 240(2):482-9. PubMed ID: 25913444 [TBL] [Abstract][Full Text] [Related]
38. An Approach to Improve Intestinal Absorption of Poorly Absorbed Water-Insoluble Components via Niemann-Pick C1-Like 1. Takekawa Y; Sato Y; Yamaki Y; Imai M; Noto K; Sumi M; Takekuma Y; Iseki K; Sugawara M Biol Pharm Bull; 2016; 39(3):301-7. PubMed ID: 26934923 [TBL] [Abstract][Full Text] [Related]
39. Lipid-lowering effects of Coffea arabica pulp aqueous extract in Caco-2 cells and hypercholesterolemic rats. Ontawong A; Duangjai A; Muanprasat C; Pasachan T; Pongchaidecha A; Amornlerdpison D; Srimaroeng C Phytomedicine; 2019 Jan; 52():187-197. PubMed ID: 30599898 [TBL] [Abstract][Full Text] [Related]
40. Can NPC1L1 inhibitors reduce the risk of biliary tract cancer? Evidence from a mendelian randomization study. Dong H; Chen R; Wang J; Chai N; Linghu E Dig Liver Dis; 2024 Sep; 56(9):1599-1604. PubMed ID: 38342741 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]